TY  - GEN
AU  - Wang,Yudong
AU  - Janku,Filip
AU  - Piha-Paul,Sarina
AU  - Hess,Kenneth
AU  - Broaddus,Russell
AU  - Liu,Lidong
AU  - Shi,Naiyi
AU  - Overman,Michael
AU  - Kopetz,Scott
AU  - Subbiah,Vivek
AU  - Naing,Aung
AU  - Hong,David
AU  - Tsimberidou,Apostolia M
AU  - Karp,Daniel
AU  - Yao,James
AU  - Fu,Siqing
TI  - Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies
SN  - 2045-2322
PY  - 2020///1112
KW  - Adult
KW  - Aged
KW  - Angiogenesis Inhibitors
KW  - adverse effects
KW  - Boron Compounds
KW  - Glycine
KW  - Humans
KW  - Indazoles
KW  - Kaplan-Meier Estimate
KW  - Middle Aged
KW  - Mutation
KW  - genetics
KW  - Neoplasms
KW  - drug therapy
KW  - Progression-Free Survival
KW  - Pyrimidines
KW  - Sulfonamides
KW  - Treatment Outcome
KW  - Tumor Suppressor Protein p53
KW  - Vorinostat
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1038/s41598-020-58366-z
ER  -